EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Results of a 28-day Phase 1b Study in NUC suppressed CHB Patients

EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients

EDP-297: A Novel, Highly Potent, Farnesoid X Receptor Agonist: Results of a Phase 1 Study in Healthy Subjects

Pharmacological Inhibition of HSD17B13 Is Hepatoprotective In Mouse Models of Liver Injury

Molecular Basis for the Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor

Molecular Basis for the Antiviral Action of EDP-235: A Potent and Selective SARS-CoV-2 3CLpro Inhibitor for the Treatment of COVID-19

EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge

Phase 1 Study of EDP-305, a Novel Once-Daily Oral Farnesoid X Receptor Agonist, in Healthy Subjects and Those with Presumptive Nonalcoholic Fatty Liver Disease

EDP-514, a Novel Pangeonotypic Class II Hepatitis B Virus Core Inhibitor: Preliminary Results of a 28-Day Phase 1b Study in NUC-Suppressed CHB Patients

EDP-514, a Potent Pangenotypic Class II Hepatitis B Virus Core Inhibitor, Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients